Skip to main content
Equibles
MCRB logo

MCRB · Seres Therapeutics, Inc. · Metrics

Track MCRB — free

Use MCRB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MCRB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.35 -0.13 (-3.74%) At close · Sep 30
Rebalance outlook locked
Going-concern doubt — flagged Aug 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“these conditions raise substantial doubt about the Company's ability to continue as a going concern. ... As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 5, 2026
Market Cap
$34.99M
Shares
9.94M
Volume · Sep 30 54.61K Avg daily vol (3M) 73.92K

MCRB metrics

65 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.35
Market cap
$34.99M

Price action

20 metrics
Price change (1W)
-13.4%
Price change (30D)
-29.1%
Price change (3M)
-55.9%
Price change (6M)
-60.8%
Price change (YTD)
-76.6%
Price change (1Y)
-81.4%
Trailing year
Price change (5Y)
—
52-week high
$28.63
52-week low
$3.48
Change from 52-week high
-87.8%
Change from 52-week low
+0.0%
Annualized volatility
88.8%
Annualized volatility (3M)
66.8%
Beta
1.3
RSI (14D)
26.1
Price vs SMA 50
-26.2%
Price vs SMA 200
-59.6%
Avg volume (3M)
74,846
Relative volume
1.0
Average dollar volume
$403,583

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.94M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
18.6×
reciprocal yield 5.4%
P / book
1.0
reciprocal yield 98.7%
FCF yield
-146.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-64.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
149.0×
reciprocal yield 0.7%
EV / revenue historical average (5Y)
97.6×
reciprocal yield 1.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-05

Profitability

9 metrics
Gross margin
—
Operating margin
-4,462.8%
Trailing 12 months
Net margin
-1,192.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$84.03M
Net income (TTM)
−$22.46M
Trailing 12 months
Diluted EPS (TTM)
$-2.45
FCF margin
-2,724.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.76

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
+4,088.2%
Revenue (TTM)
$1.88M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.5%
Year over year · more shares
Revenue CAGR (3Y)
-52.0%
Revenue CAGR (5Y)
-52.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-65.0%
Return on assets
-22.1%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
−$80.58M
Free cash flow (TTM)
−$51.30M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$15.59M
Total assets
$101.59M
Total debt
$110.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$51.26M
Capital expenditures (TTM)
$37,000
R&D (TTM)
$46.64M
SG&A (TTM)
—
Stock compensation (TTM)
$9.19M
R&D / revenue
2,476.7%
Stock compensation / revenue
487.8%

Ownership (13F)

3 metrics
13F filers
35
13F filer change QoQ
+1
Institutional ownership
24.0%

Short interest

3 metrics
Short interest
3.0%
Latest settlement · 5.7 days to cover
Days to cover
5.7d
Short-squeeze score
49 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$2,230
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1609809 CUSIP 81750R201 13F (30d) 2 filings 2 filers Visit website Investor relations